All News

Your daily dose of the clinical news you may have missed.

After a 5-year trial, the company is ending its entry into health care, citing the lack of a "sustainable business model."

Investigational treatments for congenital adrenal hyperplasia are focused on new ways to manage symptoms without the need for supraphysiologic doses of glucocorticoids.

Individuals 6 months and older should receive updated COVID-19 and influenza vaccines for the 2024-2025 respiratory virus season, the agency recommended.

Your daily dose of the clinical news you may have missed.

After performing a back blow maneuver on her 10-month-old daughter to dislodge a popcorn kernel, a mother arrives at the ED with the child in distress. What happened?

The committee endorsed a universal recommendation for a single lifetime dose of RSV vaccine for adults aged ≥75 years and a risk-based recommendation for those aged 60 to 74 years.

ADA 2024. Adults started on the Omnipod 5 AID system had an A1c reduction from 8.2% at baseline to 7.4% at 13 weeks, researchers report.

Your daily dose of the clinical news you may have missed.

ADA 2024. Adults using more antihypertensive medications had higher odds for hypercortisolism, according to new data from the CATALYST phase 4 study.

Your daily dose of the clinical news you may have missed.

This quick quiz tests what you know about updates to the 2024 ADA standards of care, which include guidance on antiobesity drugs and managing comorbid chronic disease.

Nearly one-third of US adults aged 60 years and older continue to take daily aspirin despite published evidence recommending against use in the absence of CVD.

ADA 2024. Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not they used SGLT-2 inhibitors, according to an analysis of FLOW trial data.

Your daily dose of the clinical news you may have missed.

ADA 2024. Adults with OSA and obesity receiving tirzepatide had improvements in sleep apnea severity and systolic blood pressure compared to placebo.

Your daily dose of the clinical news you may have missed.

ADA 2024. The risk of progression to stage 3 type 1 diabetes may be better predicted using a combination of patient and CGM data, a new study suggests.